Fate Therapeutics Inc SEC filings FATE
Fate Therapeutics Inc has 855 filings in SEC EDGAR's recent list, going back to May 2, 2008. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (material agreement, agreement ended). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | Nov 5, 2026 | — |
| 424B5 | Prospectus supplement | Nov 5, 2026 | — |
| S-8 | Employee stock plan registration | Aug 13, 2026 | — |
| S-8 | Employee stock plan registration | Oct 20, 2025 | — |
| S-8 | Employee stock plan registration | Jun 4, 2025 | — |
| S-8 | Employee stock plan registration | Jun 10, 2024 | — |
| 424B3 | Prospectus | May 2, 2024 | — |
| S-3 | Shelf registration | Apr 18, 2024 | — |
| 424B5 | Prospectus supplement | Mar 20, 2024 | — |
| S-3 | Shelf registration | Nov 8, 2023 | — |
| S-8 | Employee stock plan registration | Jun 9, 2022 | — |
| S-8 | Employee stock plan registration | Feb 28, 2022 | — |
| S-3ASR | Automatic shelf registration | Nov 4, 2021 | — |
| S-8 | Employee stock plan registration | Feb 24, 2021 | — |
| 424B5 | Prospectus supplement | Jan 7, 2021 | — |
| FWP | Free writing prospectus | Jan 5, 2021 | — |
| 424B5 | Prospectus supplement | Jan 4, 2021 | — |
| 424B5 | Prospectus supplement | Jun 10, 2020 | — |
| 424B5 | Prospectus supplement | Jun 8, 2020 | — |
| S-8 | Employee stock plan registration | Mar 2, 2020 | — |
| 424B5 | Prospectus supplement | Sep 13, 2019 | — |
| 424B5 | Prospectus supplement | Sep 11, 2019 | — |
| S-8 | Employee stock plan registration | Mar 8, 2019 | — |
| S-3ASR | Automatic shelf registration | Nov 21, 2018 | — |
| 424B5 | Prospectus supplement | Sep 21, 2018 | — |
| 424B5 | Prospectus supplement | Sep 20, 2018 | — |
| S-3 | Shelf registration | May 4, 2018 | — |
| S-8 | Employee stock plan registration | Mar 8, 2018 | — |
| 424B5 | Prospectus supplement | Dec 13, 2017 | — |
| 424B5 | Prospectus supplement | Dec 12, 2017 | — |
| S-8 | Employee stock plan registration | Aug 15, 2017 | — |
| S-3 | Shelf registration | Aug 15, 2017 | — |
| S-8 | Employee stock plan registration | Feb 3, 2017 | — |
| 424B3 | Prospectus | Jan 25, 2017 | — |
| S-3 | Shelf registration | Jan 6, 2017 | — |
| 424B3 | Prospectus | Sep 30, 2016 | — |
| S-3 | Shelf registration | Sep 12, 2016 | — |
| S-8 | Employee stock plan registration | May 20, 2016 | — |
| S-8 | Employee stock plan registration | Feb 4, 2016 | — |
| 424B5 | Prospectus supplement | May 21, 2015 | — |
| 424B5 | Prospectus supplement | May 18, 2015 | — |
| S-8 | Employee stock plan registration | Mar 12, 2015 | — |
| S-3 | Shelf registration | Oct 1, 2014 | — |
| S-8 | Employee stock plan registration | Mar 17, 2014 | — |
| S-8 | Employee stock plan registration | Oct 4, 2013 | — |
| 424B4 | Prospectus | Oct 1, 2013 | — |
| FWP | Free writing prospectus | Sep 30, 2013 | — |
| S-1/A | Amended registration statement | Sep 30, 2013 | — |
| S-1/A | Amended registration statement | Sep 16, 2013 | — |
| S-1/A | Amended registration statement | Sep 3, 2013 | — |
| S-1/A | Amended registration statement | Aug 29, 2013 | — |
| S-1 | Registration statement | Aug 14, 2013 | — |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FATE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434316
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.